Moderna Inc Latest Price
MRNA Moderna Stock Forecast: Performance Chart
$MRNA has underperformed the NASDAQ until recently
Moderna Stock Forecast: Observations and Insights
Recently, the Centers for disease control and prevention released data showing the percentage of people vaccinated and the number of cases per 100000 population. It showed the data for different age groups and their respective 7-day average of new covid cases. The graphs suggest that the demand for vaccination has decreased.
It can be also interpreted from the graphs that the number of covid cases per 100000 population is decreasing. So, the decrease in covid cases accompanied by the approximately constant vaccination rate led to the decrease in demand for vaccines. This can be considered the major reason for the drop in Moderna’s share price.
Modern Stock Forecast for the Next 12 Months
Moderna Stock Forecast: Latest News
- ”Moderna open to supplying COVID vaccines to China, CEO says”: Moderna had talks with the Chinese government regarding the supply of covid vaccines to china and the CEO also said that “There is about a 20% probability that a “problematic” variant of the virus could emerge this winter.”
- Singapore, Europe, Switzerland, South Korea, Taiwan, Japan, Australia, Canada, UK has approved Moderna to supply its Omicron-containing bivalent booster vaccine(Spikevax) as a booster dose. U.S. government has secured 66 million doses whereas Canada agreed to receive 12 million doses.
- Moderna has announced its quarter 2 reports (which ended on June 30th, 2022).
Its revenue is declared as $4.7billion, up 9% y-y. Its diluted EPS is $5.2 down 18% q-q. The company’s net income is $2.2billion down 20% y-y.
Moderna Stock Forecast Today
Moderna Stock Forecast: Company Background
Moderna Inc is a pharmaceutical and biotechnology company based in Cambridge, Massachusetts, focusing on RNA therapeutics and primarily mRNA vaccines. Molecule messenger RNA (mRNA) is used by these vaccines to produce an immune response. The company’s commercial product includes the Moderna COVID-19 vaccine. The company has 23 other treatment and vaccine candidates out of which 15 have entered clinical trials. Vaccine candidates include HIV, influenza, a combined single shot for COVID-19 booster, and two cancer vaccines.
The former company’s name was ModeRNA Therapeutics (2010-2018). In 2018, the company rebranded as “Moderna Inc” and further increased its portfolio. In December 2018, Moderna went public with the largest biotech IPO raising $621 million (27 million shares at $23 per share)
-Vineet Agarwal with inputs from Vaishnavi Bommu
Note: Crowdwisdom360 collates Predictions and data from all over the net and has no in-house view on the likely trends in the Stocks or Crypto Coins. Please consult a registered investment advisor to guide you on your financial decisions.